CD38 SADA
Alternative Names: CD-38-SADALatest Information Update: 06 Oct 2025
At a glance
- Originator Y-mAbs Therapeutics
- Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals; Recombinant fusion proteins
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma
Most Recent Events
- 27 Apr 2025 Pharmacokinetics data from preclinical studies in Non-Hodgkin's lymphoma released by Y-mAbs Therapeutics
- 25 Apr 2025 Pharmacokinetic data from a preclinical trial in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 07 Dec 2024 Pharmacodynamics data from a preclinical study in Non-Hodgkin's lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)